Get the Stockscreener App
14.51
0.83%
0.12
Eton Pharmaceuticals Inc stock is traded at $14.51, with a volume of 238.06K.
It is up +0.83% in the last 24 hours and down -4.98% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$14.39
Open:
$14.56
24h Volume:
238.06K
Relative Volume:
0.84
Market Cap:
$378.01M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-55.81
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
-11.61%
1M Performance:
-4.98%
6M Performance:
+250.48%
1Y Performance:
+226.07%
1-Day Range:
$14.30
$14.91
1-Week Range:
$14.18
$17.13
52-Week Range:
$3.03
$18.41
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
14.51 | 378.01M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Insider Buying: Opaleye Management Inc., Eton Pharmaceuticals Inc [ETON] 10% Owner invested 10,000 shares - Knox Daily
What Are You Thinking About Investing In Eton Pharmaceuticals Inc (NASDAQ: ETON) Stock? - Stocks Register
Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going - MSN
Learn to Evaluate (ETON) using the Charts - Stock Traders Daily
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Eton Pharmaceuticals Stock Hits All-Time High of $17.57 - MSN
FDA extends target action date for Eton's ET-400 - MSN
Eton Pharmaceuticals Receives FDA Extension for NDA for ET-400On February 6, 2025, Eton Pharmaceuticals, Inc. announced through a press release that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUF - Defense World
Eton Pharmaceuticals receives new U.S. patent for ET-600 - MSN
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors - Simply Wall St
Eton Pharmaceuticals Says US Patent Granted for ET-600 Formulation -February 07, 2025 at 07:09 am EST - Marketscreener.com
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600 - The Manila Times
Major Patent Win: Eton's Game-Changing Liquid Diabetes Drug Gets 20-Year Protection - StockTitan
Eton Pharmaceuticals Says ET-400 FDA Decision Delayed to May -February 06, 2025 at 10:15 am EST - Marketscreener.com
Eton Pharmaceuticals : FDA Extends ET-400 Review to Late May -February 06, 2025 at 08:37 am EST - Marketscreener.com
Eton Pharmaceuticals: FDA Extends ET-400 Review to Late May - MarketWatch
Eton Pharmaceuticals: FDA extends PDUFA date for NDA for ET-400 to 5/28 - TipRanks
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400 - GlobeNewswire
Eton's Pediatric Rare Disease Drug Faces 3-Month FDA Review ExtensionRevenue Outlook Unchanged - StockTitan
Baader Bank Aktiengesellschaft Takes $373,000 Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - MarketBeat
Eton Pharmaceuticals Stock Hits All-Time High of $17.57 By Investing.com - Investing.com Nigeria
New Strong Buy Stocks for January 28th - Yahoo Finance
Here's What Could Help Eton Pharmaceuticals (ETON) Maintain Its Recent Price Strength - Yahoo Finance
Biotech Stocks Facing FDA Decision In February 2025 - RTTNews
Q2 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst - MarketBeat
Q2 EPS Estimate for Eton Pharmaceuticals Raised by Analyst - Defense World
Eton Pharmaceuticals price target raised to $23 from $18 at Craig-Hallum - Yahoo Finance
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? - MSN
HC Wainwright Has Negative Outlook for ETON Q1 Earnings - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Lowered by Analyst - MarketBeat
Westside Investment Management Inc. Sells 43,453 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - MarketBeat
HC Wainwright Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) On The Verge Of Breaking Even - Simply Wall St
Eton Pharmaceuticals stock soars to all-time high of $15.11 - MSN
Eton Pharmaceuticals stock soars to all-time high of $15.11 By Investing.com - Investing.com Australia
Eton acquires Wilson disease drug Galzin - MSN
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
Eton Pharmaceuticals, Inc. (ETON): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
15,006 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Jane Street Group LLC - Defense World
Q1 Earnings Estimate for ETON Issued By B. Riley - Defense World
Q1 Earnings Forecast for ETON Issued By B. Riley - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Coverage Initiated at B. Riley - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Upgraded at B. Riley - Defense World
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eton Pharmaceuticals Inc Stock (ETON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Oct 23 '24 |
Buy |
7.98 |
10,000 |
79,814 |
2,770,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 08 '24 |
Buy |
7.03 |
33,970 |
238,782 |
2,760,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 04 '24 |
Buy |
6.77 |
16,852 |
114,105 |
2,720,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 07 '24 |
Buy |
7.22 |
11,248 |
81,250 |
2,730,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 10 '24 |
Buy |
4.65 |
57,500 |
267,375 |
2,660,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 11 '24 |
Buy |
4.75 |
50,000 |
237,500 |
2,705,000 |
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):